UCLouvain spin-off · ICTEAM · Limal, Belgium
Antimicrobial resistance — whichever mechanism, whichever host — is diagnosed 24 to 72 hours after the sample is taken, in a central lab, by trained staff. Fluiscope puts the answer at the point of need: hospital ward, farm, treatment plant. Same platform, three worlds.
* First validated assay — carbapenemase detection, CHU UCL Namur. The readout measures enzymatic activity, so the same core extends to other resistance mechanisms.
The diagnostic gap
Culture and antibiotic susceptibility testing take one to three days. In the meantime, patients receive broad-spectrum antibiotics, herds are treated preventively, and contaminated effluent is already downstream. The delay isn't an inconvenience — it is the mechanism by which resistance spreads and compounds.
Every hour without an answer is an hour of empirical treatment.
Trained staff · lab infrastructure · sample transport
No culture step · no trained operator · digital result
Isolation decisions during the admission window, not after it. Targeted therapy on day zero. Surveillance data that arrives while it can still inform an action — in a hospital, a slaughterhouse, or a wastewater plant.
One Health positioning
Most diagnostics companies pick one vertical and build a dedicated instrument for it. Fluiscope's electrochemical core and lateral-flow chemistry are the same in all three — what changes is the sample preparation, the antibody and the enzymatic substrate. That holds across resistance mechanisms as much as across sectors: one R&D investment, three regulated markets, and a panel that widens without a new instrument.
Clinical
Screening patients on arrival in ICU and high-risk wards, so isolation and therapy decisions are made in the same shift as the swab. Carbapenemases are the validated entry assay; ESBL, MRSA and further mechanisms follow on the same reader.
Veterinary & agri-food
Herd-level resistance screening and surface hygiene swabs along the food chain, where sending samples to a lab is rarely proportionate to the decision being made.
Environment
On-site AMR and microbial monitoring at treatment plants and in surface water — the surveillance layer the revised Urban Wastewater Treatment Directive turns from optional to mandatory.
The platform
A lateral-flow strip is fast and needs no operator but reads qualitatively. An electrochemical assay is quantitative and sensitive but needs an instrument. Fluiscope runs them together: the strip pre-screens, the electrode confirms, and the reader returns a single interpreted result — for any resistance mechanism the chemistry can be tuned to.
Disposable printed carbon electrodes read the electrical signature of an enzymatic reaction. Because the readout is the reaction rather than a fixed target, changing the substrate changes the resistance mechanism detected — the instrument stays the same.
Capillary migration on a paper strip with gold-nanoparticle-labelled antibodies. Result in minutes, no instrument, no trained operator, unit costs that survive routine screening.
The differentiator. Qualitative screening and quantitative confirmation in one portable kit, merged into a single interpreted output rather than two results a technician has to reconcile.
Sequenced roadmap
The order is deliberate: prove the platform where validation is strongest and the buyer is identified, then extend into markets that regulation is about to create — reusing the same reader, the same chemistry, and most of the same dossier.
Rapid resistance detection for hospital microbiology labs and infection control teams. Carbapenemase-producing Enterobacteriaceae is the first assay through clinical validation — the reference case that opens the channel for the rest of the panel.
AMR surveillance in wastewater and surface water, and resistance screening across the veterinary and agri-food chain. Demand here is created by directive, not by procurement preference.
MRSA, ESBL and further mechanisms added to the clinical menu. The highest-leverage extension: same customer, same instrument, same regulatory route as Phase 1 — a wider panel sold into a channel that already exists. Assay work, not platform work.
Business model
Fluiscope is built to do the part that is hard to copy — sensor science, assay development, integration — and to hand the rest to partners who already own manufacturing lines, quality systems and distribution in each vertical.
Custom sensor development from target to working prototype in weeks to months, for our own roadmap and under contract for industrial partners.
Patents and know-how around the hybrid platform and signal fusion, developed with UCLouvain and clinical partners. The asset the licences are written against.
Upfront fees, development milestones and per-unit royalties from diagnostics manufacturers — one licensee per vertical, revenue that scales without our headcount.
What we deliberately do not do: mass production, sales forces, or regulatory QA in every market. Those are the capital-intensive, low-margin layers our licensees already operate — and the reason a small team can address three verticals at once.
Evidence
Both pillars of the platform have been published and tested outside our own bench. Carbapenemase detection is the assay that went all the way through clinical evaluation; it is the proof that the readout works on real samples, and the template for every mechanism added after it.
Team
Co-founder · Co-managing director
PhD UCLouvain, MBA Solvay. Seven years of lateral flow assay development across academic and industrial settings.
Senior researcher · Electrochemistry
PhD in electronics. Fifteen years in electrochemical sensing; first author of the BYG Carba clinical evaluation.
Co-managing director · Business
PhD in biosciences, MBA Solvay. Leads commercial strategy, licensing and partnerships across the three verticals.
Work with us
Whether you need resistance data faster than your current lab loop allows, a sensor for a contaminant nobody sells a test for, or a platform to license into your own product line — the conversation starts the same way: what are you trying to detect, and what decision depends on it.
UCLouvain spin-off · ICTEAM · Limal, Belgium
Antimicrobial resistance — whichever mechanism, whichever host — is diagnosed 24 to 72 hours after the sample is taken, in a central lab, by trained staff. Fluiscope puts the answer at the point of need: hospital ward, farm, treatment plant. Same platform, three worlds.
* First validated assay — carbapenemase detection, CHU UCL Namur. The readout measures enzymatic activity, so the same core extends to other resistance mechanisms.
The diagnostic gap
Culture and antibiotic susceptibility testing take one to three days. In the meantime, patients receive broad-spectrum antibiotics, herds are treated preventively, and contaminated effluent is already downstream. The delay isn't an inconvenience — it is the mechanism by which resistance spreads and compounds.
Every hour without an answer is an hour of empirical treatment.
Trained staff · lab infrastructure · sample transport
No culture step · no trained operator · digital result
Isolation decisions during the admission window, not after it. Targeted therapy on day zero. Surveillance data that arrives while it can still inform an action — in a hospital, a slaughterhouse, or a wastewater plant.
One Health positioning
Most diagnostics companies pick one vertical and build a dedicated instrument for it. Fluiscope's electrochemical core and lateral-flow chemistry are the same in all three — what changes is the sample preparation, the antibody and the enzymatic substrate. That holds across resistance mechanisms as much as across sectors: one R&D investment, three regulated markets, and a panel that widens without a new instrument.
Clinical
Screening patients on arrival in ICU and high-risk wards, so isolation and therapy decisions are made in the same shift as the swab. Carbapenemases are the validated entry assay; ESBL, MRSA and further mechanisms follow on the same reader.
Veterinary & agri-food
Herd-level resistance screening and surface hygiene swabs along the food chain, where sending samples to a lab is rarely proportionate to the decision being made.
Environment
On-site AMR and microbial monitoring at treatment plants and in surface water — the surveillance layer the revised Urban Wastewater Treatment Directive turns from optional to mandatory.
The platform
A lateral-flow strip is fast and needs no operator but reads qualitatively. An electrochemical assay is quantitative and sensitive but needs an instrument. Fluiscope runs them together: the strip pre-screens, the electrode confirms, and the reader returns a single interpreted result — for any resistance mechanism the chemistry can be tuned to.
Disposable printed carbon electrodes read the electrical signature of an enzymatic reaction. Because the readout is the reaction rather than a fixed target, changing the substrate changes the resistance mechanism detected — the instrument stays the same.
Capillary migration on a paper strip with gold-nanoparticle-labelled antibodies. Result in minutes, no instrument, no trained operator, unit costs that survive routine screening.
The differentiator. Qualitative screening and quantitative confirmation in one portable kit, merged into a single interpreted output rather than two results a technician has to reconcile.
Sequenced roadmap
The order is deliberate: prove the platform where validation is strongest and the buyer is identified, then extend into markets that regulation is about to create — reusing the same reader, the same chemistry, and most of the same dossier.
Rapid resistance detection for hospital microbiology labs and infection control teams. Carbapenemase-producing Enterobacteriaceae is the first assay through clinical validation — the reference case that opens the channel for the rest of the panel.
AMR surveillance in wastewater and surface water, and resistance screening across the veterinary and agri-food chain. Demand here is created by directive, not by procurement preference.
MRSA, ESBL and further mechanisms added to the clinical menu. The highest-leverage extension: same customer, same instrument, same regulatory route as Phase 1 — a wider panel sold into a channel that already exists. Assay work, not platform work.
Business model
Fluiscope is built to do the part that is hard to copy — sensor science, assay development, integration — and to hand the rest to partners who already own manufacturing lines, quality systems and distribution in each vertical.
Custom sensor development from target to working prototype in weeks to months, for our own roadmap and under contract for industrial partners.
Patents and know-how around the hybrid platform and signal fusion, developed with UCLouvain and clinical partners. The asset the licences are written against.
Upfront fees, development milestones and per-unit royalties from diagnostics manufacturers — one licensee per vertical, revenue that scales without our headcount.
What we deliberately do not do: mass production, sales forces, or regulatory QA in every market. Those are the capital-intensive, low-margin layers our licensees already operate — and the reason a small team can address three verticals at once.
Evidence
Both pillars of the platform have been published and tested outside our own bench. Carbapenemase detection is the assay that went all the way through clinical evaluation; it is the proof that the readout works on real samples, and the template for every mechanism added after it.
Team
Co-founder · Co-managing director
PhD UCLouvain, MBA Solvay. Seven years of lateral flow assay development across academic and industrial settings.
Senior researcher · Electrochemistry
PhD in electronics. Fifteen years in electrochemical sensing; first author of the BYG Carba clinical evaluation.
Co-managing director · Business
PhD in biosciences, MBA Solvay. Leads commercial strategy, licensing and partnerships across the three verticals.
Work with us
Whether you need resistance data faster than your current lab loop allows, a sensor for a contaminant nobody sells a test for, or a platform to license into your own product line — the conversation starts the same way: what are you trying to detect, and what decision depends on it.